●Sonnet BioTherapeutics shareholders have approved a proposed merger with Hyperliquid Strategies Inc., clearing a key step for the business combination.
●The deal centers on Hyperliquid DAT, led by Paradigm, with the merged structure expected to support an on-chain HYPE treasury targeted at roughly $1 billion.
●Hyperliquid Strategies is being positioned as a high-tier, multi-point ("Quintuple-Point") Digital Asset Trust to manage and grow this HYPE-linked on-chain treasury.